A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

Also called NCT07613307

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07613307
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
India, Saudi Arabia, South Africa, United Arab Emirates (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07613307. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-15 (actual); primary completion 2027-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Acronym
ACHIEVE-RAM
Condition
Diabetes Mellitus, Type 2
Condition
Diabetes Melletus
Condition
Glucose Metabolism Disorders
Condition
Metabolic Disorders
Condition
Nutritional and Metabolic Diseases
Condition
Endocrine System Diseases
Condition
Feeding Behavior
Condition
Behavior
Condition
Fasting
Condition
Glucagon-Like Peptide-1 Receptor
Condition
Glucagon-Like Peptide Receptors
Condition
Receptors, G-Protein-Coupled
Condition
Receptors, Cell Surface
Condition
Membrane Proteins
Condition
Proteins
Condition
Receptors, Peptide
Intervention (Drug)
Orforglipron
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07613307
Content hash
ef90600f586931cdcbc18e5dd98efa996f53682ca11e029a73e32fe285fe8cbe